Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CODEXIS, INC.CDXS · Entity 6428 | Chief Operating Officer | February 05, 2025 | February 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CODEXIS, INC.
Report date February 05, 2025 · Filed February 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,327 |
Reported balance
After 2025-02-05 transaction · row 1
1 source rowRow 1 · 2025-02-05 · Grant · Acquired 26,875 · Balance 177,327 F1: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37 · Expires 2035-02-05 | Direct | 161,250 |
Reported balance
After 2025-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-05 · Grant · Acquired 161,250 · Balance 161,250 F2: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates.
F2: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 17,786 · Balance 0 F1: These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.25 · Expires 2035-11-17 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 64,286 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.65 · Expires 2036-01-21 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Disposition to issuer · Disposed 4,000 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05 · Expires 2030-08-10 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1: The option vested as to 25% of the total shares on August 10, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 49,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.73 · Expires 2031-03-15 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 11,700 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.54 · Expires 2032-03-14 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% of the total shares on August 10, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F3: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 18, 2026 20:42 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 4,000 | Not disclosed Strike: $43.65 | Not disclosed |
DisclosureSEC source: 0001819690-26-000004 · form4-05182026_080545.xml · derivative · entry 3 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2036-01-21 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:42 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 64,286 | Not disclosed Strike: $47.25 | Not disclosed |
DisclosureSEC source: 0001819690-26-000004 · form4-05182026_080545.xml · derivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,286 shares Expires 2035-11-17 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:42 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerCommon Stock | 17,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819690-26-000004 · form4-05182026_080545.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2 · price: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 23:07 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 4,000 | $0.00 Strike: $43.65 | $0.00 |
DisclosureSEC source: 0001819690-26-000002 · form4-01232026_110102.xml · derivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2036-01-21 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 23:07 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001819690-26-000002 · form4-01232026_110102.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,786 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date. F2 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 64,286 | $0.00 Strike: $47.25 | $0.00 |
DisclosureSEC source: 0001819690-25-000008 · form4-11192025_111147.xml · derivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,286 Underlying: Common Stock · 64,286 shares Expires 2035-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on November 17, 2026 and one forty-eighth of the shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 14,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001819690-25-000008 · form4-11192025_111147.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,286 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 17, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. F1 · balance_after: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 17, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 01:20 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 161,250 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0000905148-25-000444 · form4.xml · derivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,250 Underlying: Common Stock · 161,250 shares Expires 2035-02-05 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 01:20 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 26,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000444 · form4.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,327 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 02:24 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 314,125 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0000905148-24-000031 · form4.xml · derivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,125 Underlying: Common Stock · 314,125 shares Expires 2034-01-01 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 1/3rd of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/36th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 02:24 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 52,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000031 · form4.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,452 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 20:07 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 9,000 | $1.72 | $15,479.10 |
DisclosureSEC source: 0000905148-23-000902 · form4.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,102 Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 02:16 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 8,258 | $4.56 | $37,616.84 |
DisclosureSEC source: 0001567619-23-004773 · doc1.xml · nonDerivative · entry 3 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,102 F2 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSUs of the Issuer. F3 · price: Reflects the weighted average of all shares sold to cover taxes upon vesting of PSUs on March 8, 2023 for certain employees of the Issuer. Read SEC document |
| March 07, 2023 Filed Mar 10, 2023 02:16 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 8,596 | $4.60 | $39,564.81 |
DisclosureSEC source: 0001567619-23-004773 · doc1.xml · nonDerivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,360 F2 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSUs of the Issuer. F3 · price: Reflects the weighted average of all shares sold to cover taxes upon vesting of PSUs on March 8, 2023 for certain employees of the Issuer. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 01:28 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 67,500 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001567619-23-003443 · doc1.xml · derivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2033-02-21 F2 · derivative.exercise_date: Option vests and becomes exercisable with respect to 25% of the shares subject thereto on February 21, 2024, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on February 21, 2027, in each case, subject to continued service through the applicable vesting date. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 01:28 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003443 · doc1.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · shares: Restricted Stock Units ("RSUs") vest 1/3 annually from February 21, 2023 such that the RSUs will be fully vested on February 21, 2026. Each RSU represents a contingent right to receive one share of Codexis common stock. Read SEC document |
| February 08, 2023 Filed Mar 10, 2023 02:16 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 83,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004773 · doc1.xml · nonDerivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,956 F1 · shares: Represents restricted stock awards ("PSUs") initially granted on November 8, 2022 that were subject a performance-based vesting condition. The vesting condition was determined to be 85% satisfied on February 8, 2023. The PSUs will vest fully on March 5, 2024, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:17 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 413,405 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001567619-22-018272 · doc1.xml · derivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,405 Underlying: Common Stock · 413,405 shares Expires 2032-10-03 F1 · derivative.exercise_date: Option vests and becomes exercisable with respect to 25% of the shares subject thereto on October 3, 2023, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on October 3, 2026, in each case, subject to continued service through the applicable vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:28 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $31.54 | $0.00 |
DisclosureSEC source: 0001209191-22-040236 · doc4.xml · derivative · entry 4 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2032-03-14 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F5 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:28 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 11,700 | $0.00 Strike: $16.73 | $0.00 |
DisclosureSEC source: 0001209191-22-040236 · doc4.xml · derivative · entry 3 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,700 shares Expires 2031-03-15 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4 · derivative.exercise_date: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:28 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-040236 · doc4.xml · derivative · entry 2 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,000 shares Expires 2030-08-12 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3 · derivative.exercise_date: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:28 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-040236 · doc4.xml · derivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2030-08-10 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1 · derivative.exercise_date: The option vested as to 25% of the total shares on August 10, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:16 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-037847 · doc4.xml · derivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document |
| March 14, 2022 Filed Mar 14, 2022 16:43 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $31.54 | $0.00 |
DisclosureSEC source: 0001209191-22-018486 · doc4.xml · derivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 28, 2022 Filed Jan 28, 2022 18:33 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005483 · doc4.xml · derivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:17 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 11,700 | $0.00 Strike: $16.73 | $0.00 |
DisclosureSEC source: 0001209191-21-021622 · doc4.xml · derivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:54 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-20-046213 · doc4.xml · derivative · entry 1 Norrett Kevin · CIK 0001819690 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-10 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on August 10, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.